We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
0%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$879M
AUM Growth
-$188M
Cap. Flow
-$188M
Cap. Flow %
-21.43%
Top 10 Hldgs %
100%
Holding
51
New
5
Increased
–
Reduced
–
Closed
46

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$237M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$84.4M
3
ARWR icon
Arrowhead Research
ARWR
+$73.3M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$56.2M
5
CDXS icon
Codexis
CDXS
+$48.2M

Sector Composition

Rank Sector Weight
1 Healthcare 0%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$751M
– –
-1,647,214
Closed -$3.61M
AKTX
2
Akari Therapeutics
AKTX
$16.7M
– –
-432
Closed -$699K
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
– –
-383,538
Closed -$9.72M
ARWR icon
4
Arrowhead Research
ARWR
$12.1B
– –
-2,765,153
Closed -$73.3M
ASND icon
5
Ascendis Pharma A/S
ASND
$16.7B
– –
-2,060,135
Closed -$237M
AUPH icon
6
Aurinia Pharmaceuticals
AUPH
$2.01B
– –
-1,913,623
Closed -$12.6M
CDXS icon
7
Codexis
CDXS
$138M
– –
-2,614,458
Closed -$48.2M
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$8.87B
– –
-3,375,169
Closed -$84.4M
DBVT
9
DBV Technologies
DBVT
$822M
– –
-27,000
Closed -$2.22M
DTIL icon
10
Precision BioSciences
DTIL
$189M
– –
-9,350
Closed -$3.72M
GLMD icon
11
Galmed Pharmaceuticals
GLMD
$3.86M
– –
-5,396
Closed -$7.14M
INSM icon
12
Insmed
INSM
$23.2B
– –
-1,748,174
Closed -$44.8M
IOVA icon
13
Iovance Biotherapeutics
IOVA
$2.18B
– –
-1,600,000
Closed -$39.2M
KALA icon
14
KALA BIO
KALA
$11.5M
– –
-418
Closed -$6.65M
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
– –
-1,359,149
Closed -$30.1M
KNSA icon
16
Kiniksa Pharmaceuticals
KNSA
$4.86B
– –
-843,478
Closed -$11.4M
LITS
17
Lite Strategy Inc
LITS
$33.7M
– –
-284,070
Closed -$14.2M
MTNB icon
18
Matinas BioPharma
MTNB
$2.41M
– –
-136,364
Closed -$5.84M
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$363M
– –
-786,712
Closed -$11.8M
RNAC icon
20
Cartesian Therapeutics
RNAC
$233M
– –
-18,202
Closed -$977K
SLNO
21
DELISTED
Soleno Therapeutics
SLNO
– –
-284,597
Closed -$12M
VRNA
22
DELISTED
Verona Pharma
VRNA
– –
-1,492,951
Closed -$7.61M
VYNE icon
23
VYNE Therapeutics
VYNE
$16.6M
– –
-1,114
Closed -$24M
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.29B
– –
-1,405,476
Closed -$13.9M
ZYME icon
25
Zymeworks
ZYME
$1.69B
– –
-1,453,467
Closed -$32M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
WC
Whitney & Co Rochester, New York $1.2B AUM 24.16% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
TWM
Tanglewood Wealth Management Houston, Texas $1.21B AUM 19.59% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return

Vivo Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Vivo Capital held 51 positions worth $879M, down 18% from $1.07B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Vivo Capital withdrew a net $188M in Q3 2019, closing 46 positions. Its most notable exit was Ascendis Pharma A/S, an estimated $237M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 0% of assets, down from 95% a quarter earlier, followed by Materials.

  • Vivo Capital fully exited Ascendis Pharma A/S in Q3 2019, selling an estimated $237M.
  • Vivo Capital's ten largest holdings make up 100% of its $879M portfolio in Q3 2019.
  • Vivo Capital opened 5 new positions and closed 46 in Q3 2019.
  • Vivo Capital's portfolio value fell 18% quarter-over-quarter to $879M.

Based on Vivo Capital's 13F filing for Q3 2019, filed 13 Nov 2019.